SCHEMBL9869077

SCHEMBL9869077

CN(C=O)CC1OCCO1

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL327494 0.72
SCHEMBL1245013 0.71 ALDH1A1 (0.41) USP2
SCHEMBL10059147 0.70 PIK3CD (0.34) USP2ALOX15
SCHEMBL2918731 0.69
SCHEMBL9869071 0.68
SCHEMBL6825745 0.67 NAMPT (0.34)
SCHEMBL14030019 0.67 SLC6A4 (0.32)
SCHEMBL5468024 0.67 NAMPT (0.36)
SCHEMBL4107607 0.67 NAMPT (0.36)
SCHEMBL11434822 0.67 NAMPT (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11090413-B2 Modified alginates for anti-fibrotic materials and applications MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-08-17 US disclosed
US-20190184067-A1 MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY 2019-06-20 US disclosed
US-20170226232-A1 MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2017-08-10 US disclosed
WO-1991011448-A1 THERAPEUTIC AGENTS THE BOOTS COMPANY PLC (GB) 1991-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170226232-A1 MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS ALG1, FIBP, COL2A1 USP2 1391/4885ALOX15 1044/4885
US-11090413-B2 Modified alginates for anti-fibrotic materials and applications ALG1, FIBP, COL2A1 USP2 1391/4885ALOX15 1044/4885
US-20190184067-A1 MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS ALG1, FIBP, COL2A1 USP2 1391/4885ALOX15 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.